Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 16/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21396779 | 0.89 | LRRK2 (0.34) | TGFBR1MAPK14RPS6KB1ROCK1 | |
| SCHEMBL21396745 | 0.85 | GABRA1 (0.35) | TGFBR1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL21396957 | 0.85 | TGFBR1 (0.34) | TGFBR1RPS6KB1ROCK1 | |
| SCHEMBL21396659 | 0.83 | SMN1; SMN2 (0.35) | — | |
| SCHEMBL21397052 | 0.83 | KDM4E (0.35) | GABRA1GABRG2GABRB3GABRA3GSK3B | |
| SCHEMBL21396943 | 0.81 | HTT (0.39) | TGFBR1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL21396743 | 0.81 | HTT (0.39) | TGFBR1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL21397148 | 0.80 | GRM5 (0.34) | TGFBR1GSK3BDYRK1A | |
| SCHEMBL21397023 | 0.80 | GRM5 (0.34) | TGFBR1GSK3BDYRK1A | |
| SCHEMBL21929600 | 0.79 | PDE4B (0.39) | RPS6KB1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190296247-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND POLYCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190296247-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND POLYCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE | SLC25A21, SLCO4C1, SLC18A1 | TGFBR1 3412/4885GABRA1 2479/4885GABRG2 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.